Molecular assessment of drug resistance in Plasmodium falciparum from Bahr El Gazai Province, Sudan

Tropical Medicine and International Health

Volumn 8, Issue 12, 2003, Pages 1068-1073

  Anderson, Tim J C ^a   Nair, Shalini ^a   Jacobzone, Corine ^b   Zavai, Andes ^b   Balkan, Suna ^b  

^a SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

Chloroquine; dhfr; dhps; pfcrt; pfmdr; Pyrimethamine sulphadoxine

Indexed keywords

ABC TRANSPORTER; ANTIMALARIAL AGENT; ARTEMISININ; CARRIER PROTEIN; CHLOROQUINE; CHLOROQUINE RESISTANCE TRANSPORTER; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; DNA; FANSIDAR; MDR GENE PROTEIN, PLASMODIUM; MEMBRANE PROTEIN; MOLECULAR MARKER; MULTIDRUG RESISTANCE PROTEIN 1; PFCRT PROTEIN; PROTOZOAL PROTEIN; PYRIMETHAMINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE; UNCLASSIFIED DRUG;

DRUG RESISTANCE;

ALLELE; ANIMAL; ARTICLE; BLOOD SAMPLING; CODON; CONTROLLED STUDY; DHFR GENE; DHPS GENE; DRUG COMBINATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESISTANCE; GENE; GENE FREQUENCY; GENE MUTATION; GENETICS; GENOTYPE; HUMAN; HUMAN TISSUE; MALARIA; MUTATION; PFCRT GENE; PFMDR1 GENE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; SUDAN; TREATMENT FAILURE;

ANIMALS; ANTIMALARIALS; ATP-BINDING CASSETTE TRANSPORTERS; CHLOROQUINE; DIHYDROPTEROATE SYNTHASE; DRUG COMBINATIONS; DRUG RESISTANCE; GENE FREQUENCY; GENOTYPE; HUMANS; MEMBRANE PROTEINS; MUTATION; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; PYRIMETHAMINE; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE; TREATMENT FAILURE;

ANIMALIA; PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 0346216115     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1360-2276.2003.01144.x     Document Type: Article

References (18)

1. Babiker HA, Pringle SJ, Abdel-Muhsin A et al. (2001) High-level chloroquine resistance in Sudanese isolates of Plasmodium falciparum is associated with mutations in the chloroquine resistance transporter gene pfcrt and the multidrug resistance gene pfmdr1. Journal of Infectious Diseases 183, 1535-1538.
2. van den Broek IVF, Gatkoi T, Lowoko B et al. (2003) Chloroquine, sulfadoxine/pyrimethamine and amodiaquine efficacy for the treatment of uncomplicated falciparum malaria in Upper Nile, south Sudan. Transactions of the Royal Society for Tropical Medicine and Hygiene 97, 229-235.
3. Djimde A, Doumbo OK, Cortese JF et al. (2001a) A molecular marker for chloroquine-resistant falciparum malaria. New England Journal of Medicine 344, 257-263.
4. Djimde A, Doumbo OK, Steketee RW & Plowe CV (2001b) Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet 358, 890-891.
5. Fidock DA, Nomura T, Talley AK et al. (2000) Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Molecular Cell 6, 861-871.
6. Hartl DL & Clark AG (1997) Principles of Population Genetics, 3rd edn. Sinauer Associates, Sunderland, pp. 1-542.
7. Jelinek T, Aida AO, Peyerl-Hoffmann G et al. (2002) Diagnostic value of molecular markers in chloroquine-resistant falciparum malaria in Southern Mauritania. American Journal of Tropical Medicine and Hygiene 67, 449-453.
8. Khalil I, Alifrangis M, Ronn AM et al. (2002) Pyrimethamine/sulfadoxine combination in the treatment of uncomplicated falciparum malaria: relation between dihydropteroate synthase/dihydrofolate reductase genotypes, sulfadoxine plasma levels, and treatment outcome. American Journal of Tropical Medicine and Hygiene 67, 225-229.
9. Kublin JG, Dzinjalamala FK, Kamwendo DD et al. (2002) Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. Journal of Infectious Diseases 185, 380-388.
10. Mendez F, Munoz A, Carrasquilla G et al. (2002) Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. American Journal of Epidemiology 156, 230-238.
11. Nair S, Brockman A, Paiphun L, Nosten F, & Anderson TJ (2002) Rapid genotyping of loci involved in antifolate drug resistance in Plasmodium falciparum by primer extension. International Journal of Parasitology 32, 852-858.
12. Nair S, Williams JT, Brockman A et al. (2003) A selective sweep driven by pyrimethamine treatment in SE Asian malaria parasites. Molecular Biology and Evolution 20, 1526-1536.
13. Plowe CV, Kublin JG & Doumbo OK (1998) P. falciparum dihydrofolate reductase and dihydropteroate synthase mutations epidemiology and role in clinical resistacne to antifolates. Drug Resistance Updates 1, 389-396.
14. Price RN, Nosten F, Luxemburger C et al. (1996) Effects of artemisinin derivatives on malaria transmissibility. Lancet 347, 1654-1658.
15. Roper C, Pearce R, Bredenkamp B et al. (2003) Antifolate antimalarial resistance in southeast Africa: a population-based analysis. Lancet 361, 1174-1181.
16. von Seidlein L, Milligan P, Pinder M et al. (2000) Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. Lancet 355, 352-357.
17. Targett G, Drakeley C, Jawara M et al. (2001) Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. Journal of Infectious Diseases 183, 1254-1259.
18. White NJ (1999) Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 41, 301-308.